

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Desmond MASCARENHAS
Title: NULL IGF FOR THE TREATMENT OF CANCER
Appl. No.: 09/399,120
Filing Date: 09/20/1999
Examiner: F. T. MOEZIE
Art Unit: 1653

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.113, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

The foregoing documents were cited as being relevant in the International Search Report of Applicant's corresponding International Application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of an information disclosure statement under 37 C.F.R. §1.97(c) in the amount of \$180.00 in accordance with 37 C.F.R. §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date March 12, 2002

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407

Facsimile: (202) 672-5399

Respectfully submitted,

By

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Form PTO-1449

(MODIFIED)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

057491-0413

SERIAL NO.

09/399,120

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Desmond MASCARENHAS

FILING DATE

09/20/1999

GROUP ART UNIT

1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,310,742	05/10/1994	ELIAS	514	274	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A2	95/16703	06/22/1995	WO				
	A3	98/36764	08/27/1998	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A4	PASCASIO, F.M. et al. "Methimazole in the Treatment of Hepatocellular Carcinoma (A Pilot Study)," <i>Phil. J. Internal Medicine</i> (1981), Vol. 19, No. 2, pp. 80 - 84.					

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.